Biomarker-Driven Lung Cancer

During a Targeted Oncology™ Case-Based Roundtable™ event, Timothy F. Burns, MD, PhD, discussed the use of sotorasib and adagrasib for patients with KRAS-mutated non–small cell lung cancer including those with brain metastases.

The investigational antibody-drug conjugate, MYTX-011, is one step further in development for the treatment of non–small cel lung cancer with cMET overexpression.

A new treatment geared to treat the most common driver of RAS-addicted solid tumors has been dosed for the first time in humans.

Based on safety and efficacy data from KontRASt-01 trial, the SP2/KRAS G12C inhibitor regimen will be investigated future.

Joshua K. Sabari, MD, discusses the importance of targeting the KRAS biomarker and what inhibitors currently exist for patients with KRAS G12C-mutant advanced solid tumors.

The BEAMION Lung-1 trial of zongertinib in HER2–mutant solid tumors is advancing to phase 1b following encouraging preliminary results.

The phase 3 IMpower151 study has missed it primary end point of progression-free survival.

Manmeet Ahluwalia, MD, discusses brain metastases in patient with biomarker-driven lung cancer and outcomes of these patients.

The median progression-free survival rates were 19.3 months with brigatinib and 19.2 months with alectinib in the phase 3 ALTA-3 study for patients with ALK-positive non–small cell lung cancer.

No significant difference in efficacy outcomes were shown with bintrafusp alfa vs pembrolizumab in patients with PD-L1-high, advanced non–small cell lung cancer. However, further investigation may offer more information about the benefit of this drug class.

Joshua K. Sabari, MD, discusses LY3537982 for patients with KRAS G12C-mutant advanced solid tumors.

Phase 1 results with the KRAS G12C inhibitor garsorasib did not show an immediate advantage with the latest KRAS G12C inhibitor but show that investigations into these inhibitors continue to grow.

According to experts, genomic testing is a key tool impacting treatment decisions for physicians treating patients with non–small cell lung cancer.

Liza C. Villaruz, MD, discusses what research in the KRAS G12C-mutated non–small cell lung cancer space has appeared to be most promising in recent years.

Progression-free survival data from the phase 3 TROPION-Lung01 trial showed that datopotamab deruxtecan as treatment of metastatic non–small cell lung cancer crossed the threshold for statistical significance.

During a Targeted Oncology™ Case-Based Roundtable™ event, Ticiana Leal, MD, discussed the use of sotorasib and adagrasib in patients with KRAS G12C mutations in non–small cell lung cancer.

Findings from the 5-year follow-up analysis of the phase 3 KEYNOTE-042 study continue to support frontline pembrolizumab as standard of care for PD-L1-positive, locally advanced/metastatic non–small cell lung cancer.

During a Targeted Oncology™ Case-Based Roundtable™ event, D. Ross Camidge, MD, PhD, discussed dosing and toxicity concerns with the KRAS inhibitors adagrasib and sotorasib.

Joshua K. Sabari, MD, discusses LY3537982 for patients with KRAS G12C-mutant advanced solid tumors.

Individual data from 2 studies evaluating rezivertinib in patients with advanced non–small cell lung cancer harboring an EGFR T790M mutation and CNS metastases displayed encouraging efficacy and safety findings.

In most key prespecified molecularly defined subsets of patients with pretreated KRAS G12C–mutated non–small cell lung cancer, sotorasib continued to demonstrate consistent benefit vs docetaxel.

In an interview with Targeted Oncology, Liza C. Villaruz, MD, discussed important new therapies for biomarker-driven NSCLC, and novel biomarkers that may bring new treatments in the near future.

Results from TRIDENT-1 are supporting a new drug application for repotrectinib, a potential treatment for ROS1-positive advanced non–small cell lung cancer.

Liza C. Villaruz, MD, discusses the latest areas of growth in the non–small cell lung cancer space.

Looking at real-world data, researchers identified a large increase of biomarker testing for patients with early-stage non–small cell lung cancer, which indicates a continuing trend toward personalized treatment.